Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Views - In 2025, the company achieved revenue and net profit attributable to shareholders of HKD 14.579 billion and HKD 0.980 billion, respectively, representing year-on-year growth of 11.5% and 14.8% [2][6] - The main drivers for revenue growth include the expansion of tobacco leaf exports (through channel development and price increases) and an increase in the self-operated ratio of cigarette exports [2][6] - The company plans to distribute a dividend of HKD 0.52 per share in 2025, reflecting a year-on-year increase of 13.0%, with a payout ratio of approximately 37% [2][6] Revenue Breakdown - Tobacco Leaf Import Business: Revenue increased by 15.6% year-on-year to HKD 9.54 billion, with a slight decline in import volume by 1.0% and a price increase of 17% [11] - Tobacco Leaf Export Business: Revenue rose by 20.4% year-on-year to HKD 2.48 billion, with export volume increasing by 3.1% and prices up by 17% [11] - Cigarette Export Business: Revenue grew by 5.9% year-on-year to HKD 1.67 billion, despite a decline in export volume by 3.3% [11] - New Tobacco Products: Revenue decreased by 51.2% year-on-year to HKD 0.064 billion, with the business under pressure due to geopolitical conflicts and regulatory changes [11] - Brazilian Operations: Revenue fell by 21.0% year-on-year to HKD 0.83 billion, impacted by shipping schedules and market price declines [11] Future Outlook - The company is positioned as a unique player in the tobacco export market, with strong growth potential driven by both organic and external expansion strategies [11] - The expected net profits for 2026-2028 are projected to be HKD 1.13 billion, HKD 1.36 billion, and HKD 1.55 billion, respectively, with corresponding price-to-earnings ratios of 24, 20, and 17 [11]

Investment Rating - The investment rating for China Tobacco Hong Kong (6055.HK) is upgraded to "Buy" [1]. Core Insights - The company demonstrated robust performance in 2025, with revenue and profit both showing double-digit growth. The dividend payout ratio remains stable. The company actively integrates resources across categories and markets, achieving progress in tobacco leaves, cigarettes, and Brazilian operations, contributing to sustained growth [2]. Financial Summary - Total revenue for 2025 is projected at HKD 14,579 million, reflecting a year-on-year increase of 11.5% - Net profit is expected to reach HKD 980 million, up 14.8% year-on-year - Gross profit margin stands at 10.1%, a decrease of 0.4 percentage points - For the second half of 2025, revenue is estimated at HKD 4,260 million, down 2.5%, while net profit is projected at HKD 270 million, an increase of 30.2% - The company plans to pay dividends of HKD 0.32, HKD 0.46, and HKD 0.52 per share for 2023-2025, maintaining a dividend payout ratio of around 37% [4][10]. Revenue Breakdown - Revenue from imported tobacco leaves is expected to be HKD 9,540 million, up 15.6% year-on-year (volume down 1.0%, price up 16.8%) - Revenue from exported tobacco leaves is projected at HKD 2,480 million, an increase of 20.4% year-on-year (volume up 3.1%, price up 16.8%) - Revenue from cigarette exports is estimated at HKD 1,670 million, up 5.9% year-on-year (volume down 3.3%, price up 9.6%) - Revenue from new tobacco products is expected to decline to HKD 60 million, down 52.4% year-on-year (volume down 51.2%, price down 2.6%) - Revenue from Brazilian operations is projected at HKD 830 million, down 21.0% year-on-year (volume down 4.2%, price down 17.6%) [10]. Future Projections - The company has raised its EPS forecasts for 2026 and 2027 to HKD 1.64 and HKD 1.95, respectively, with a target price of HKD 44 based on a 27x PE for 2026. The expected EPS for 2028 is HKD 2.21 [10][12].

Core Viewpoint - Cathay Securities maintains a "Buy" rating for China Tobacco Hong Kong (06055) and raises the EPS forecast for 2026-2027 to HKD 1.64/1.95 from HKD 1.58/1.75, with a target price of HKD 44 based on a 27X PE for 2026, considering the company's growth potential and expansion logic [1] Group 1: Financial Performance - The company expects a stable performance in 2025, with projected revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit of HKD 980 million, up 14.8%, with a gross margin of 10.1%, down 0.4 percentage points [1] - For the second half of 2025, revenue is anticipated to be HKD 4.26 billion, down 2.5%, while net profit is expected to rise by 30.2% to HKD 270 million, suggesting a need to view the full year performance collectively [1] - Shareholder returns are projected with dividends of HKD 0.32/0.46/0.52 per share for 2023-2025, maintaining a payout ratio of around 37% [1] Group 2: Revenue Breakdown - For 2025, the revenue from imported tobacco leaf products is expected to be HKD 9.54 billion, a year-on-year increase of 15.6%, with a decrease in gross margin by 1.9 percentage points due to increased costs from Brazilian tobacco leaf procurement [2] - Revenue from exported tobacco leaf products is projected at HKD 2.48 billion, up 20.4%, with a gross margin increase of 2.2 percentage points, benefiting from price increases [2] - Revenue from cigarette exports is expected to reach HKD 1.67 billion, a 5.9% increase, with a gross margin improvement of 5.2 percentage points to 22.8%, driven by a higher proportion of duty-free self-operated sales [2] - New tobacco product exports are projected to decline significantly by 52.4% to HKD 60 million, primarily due to international events [2] - The Brazilian operations are expected to generate HKD 830 million, down 21.0%, influenced by both volume and price declines [2] Group 3: Strategic Initiatives - The company is actively expanding its business by integrating resources and exploring new markets, with changes in tobacco leaf and cigarette export operations expected in 2026 [3] - The company has initiated tobacco leaf procurement from China Tobacco North America and sales to third parties, with expected transaction limits significantly higher than in 2025 [3] - As the only state-owned enterprise with the qualification to export cigarettes to the domestic duty-free market, China Tobacco Hong Kong is expected to enhance its revenue and profitability through collaboration with China Tobacco International [3]

Core Viewpoint - Cathay Securities maintains a "Buy" rating for China Tobacco Hong Kong (06055) and raises the EPS forecast for 2026-2027 to HKD 1.64/1.95 from HKD 1.58/1.75, with a target price of HKD 44 based on a 27X PE for 2026, considering the company's growth potential and expansion logic [1] Group 1: Financial Performance - The company expects a stable performance in 2025, with projected revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit of HKD 980 million, up 14.8%, with a gross margin of 10.1%, down 0.4 percentage points [1] - For the second half of 2025, revenue is anticipated to be HKD 4.26 billion, down 2.5%, while net profit is expected to rise by 30.2% to HKD 270 million, suggesting a need to view the full year performance collectively [1] - The company plans to distribute dividends of HKD 0.32/0.46/0.52 per share from 2023 to 2025, maintaining a payout ratio of around 37% [1] Group 2: Revenue Breakdown - For 2025, the revenue from imported tobacco leaf products is projected at HKD 9.54 billion, a year-on-year increase of 15.6%, with a decrease in gross margin by 1.9 percentage points due to rising costs from Brazilian tobacco leaf procurement [2] - Revenue from exported tobacco leaf products is expected to reach HKD 2.48 billion, up 20.4%, with a gross margin increase of 2.2 percentage points, benefiting from price increases [2] - Revenue from cigarette exports is projected at HKD 1.67 billion, a 5.9% increase, with a gross margin improvement of 5.2 percentage points to 22.8%, driven by a higher proportion of duty-free self-operated sales [2] - New tobacco product exports are expected to decline significantly by 52.4% to HKD 60 million, primarily due to international events [2] - Revenue from Brazilian operations is projected to decline by 21.0% to HKD 830 million, influenced by changes in product structure [2] Group 3: Business Expansion - The company is actively expanding its business by integrating resources and exploring new markets, with changes in tobacco leaf and cigarette export operations expected in 2026 [3] - The company has initiated tobacco leaf procurement from China Tobacco North America and sales to third parties, with expected transaction limits significantly higher than in 2025 [3] - As the only state-owned enterprise with the qualification to export cigarettes to the domestic duty-free market, China Tobacco Hong Kong is expected to enhance its revenue and profitability through collaboration with China Tobacco International [3]

Investment Rating - The report maintains a "Buy" rating for China Tobacco Hong Kong (06055.HK) [1] Core Views - The company reported a steady growth in overall performance, with 2025 revenue and net profit increasing by 11.5% and 14.8% year-on-year, reaching HKD 14.579 billion and HKD 980 million respectively [1] - The second half of 2025 saw a slight decline in revenue by 2.46% but a significant increase in net profit by 30.20% [1] - The company declared a dividend of HKD 0.33 per share for the full year of 2025 [1] Operational Analysis - The company experienced significant increases in the unit price of imported tobacco leaves and exported cigarettes, contributing to stable revenue growth [2] - For 2025, revenue from tobacco leaf exports, imports, cigarette exports, new tobacco products, and Brazilian operations reached HKD 2.481 billion, HKD 9.538 billion, HKD 1.666 billion, HKD 0.64 billion, and HKD 0.829 billion respectively, with year-on-year growth rates of 20.37%, 15.55%, 5.89%, -52.46%, and -21.03% [2] - The second half of 2025 showed a strong performance with revenue growth of 34.8%, 40.2%, and 23.2% for tobacco leaf imports, exports, and cigarette exports respectively [2] Profitability and Margin Analysis - The company's gross margin and net margin for 2025 were 10.10% and 7.18%, reflecting a decrease of 0.44 and an increase of 0.27 percentage points respectively [3] - The gross margin for tobacco leaf exports, imports, cigarette exports, new tobacco products, and Brazilian operations were 6.3%, 8.1%, 22.8%, 5.3%, and 19.4% respectively [3] - The company is expected to see a recovery in gross margins due to an increase in self-operated channels and improved product mix [3] Earnings Forecast and Valuation - The report forecasts earnings per share (EPS) for 2025, 2026, and 2027 to be HKD 1.59, HKD 1.86, and HKD 2.19 respectively, with corresponding price-to-earnings (P/E) ratios of 23, 20, and 17 times [4]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 46.80 [1]. Core Views - The company achieved a revenue of HKD 14.58 billion in 2025, representing a year-on-year growth of 11.5%, and a net profit of HKD 980 million, up 14.8% year-on-year, slightly exceeding previous expectations [1]. - The company's robust revenue growth amidst external disruptions is attributed to improved gross margins in leaf and cigarette exports, indicating a strong operational performance [1]. - As the only listed platform under China Tobacco, the company has a strong competitive moat and is expected to continue its growth trajectory in core business areas, supported by ongoing breakthroughs in leaf and cigarette export operations [1]. Revenue and Profitability - The combined revenue from leaf import and export business reached HKD 12.02 billion in 2025, a year-on-year increase of 16.5%, accounting for 82.4% of total revenue [2]. - The leaf import business generated HKD 9.54 billion in revenue, up 15.6% year-on-year, driven by an increase in average selling prices despite a slight decline in import volume [2]. - The leaf export business saw revenue of HKD 2.48 billion, a 20.4% increase year-on-year, with both export volume and average price rising, benefiting from enhanced customized services and pricing strategies [2]. Sales Performance - The cigarette export business generated HKD 1.67 billion in revenue, reflecting a 5.9% year-on-year increase, although export volume decreased by 3.3% due to shipping rhythm impacts [3]. - New tobacco product exports faced significant declines, with volumes down 51.2% year-on-year, resulting in a revenue drop of 52.5% [3]. - The company's operations in Brazil reported a revenue of HKD 830 million, down 21.0% year-on-year, primarily due to shipping rhythm and market changes [3]. Profitability Metrics - The overall gross margin for the company was 10.1% in 2025, a decrease of 0.4 percentage points year-on-year, mainly due to the higher proportion of lower-margin leaf import and export business [4]. - The net profit margin for the company was 6.7%, an increase of 0.2 percentage points year-on-year, supported by reduced management and financial expense ratios [4]. - The company has announced several important updates indicating ongoing progress in its export business, suggesting continued growth potential [4]. Earnings Forecast and Valuation - The earnings forecast for 2026-2028 has been slightly adjusted downwards, with expected net profits of HKD 1.08 billion, HKD 1.20 billion, and HKD 1.32 billion respectively [5]. - The company is assigned a target PE of 30 times for 2026, reflecting its unique market position and long-term growth potential, with a revised target price of HKD 46.80 [5].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a solid revenue growth of HKD 14.58 billion for the fiscal year ending December 31, 2025, representing a year-on-year increase of 11.5%. The net profit attributable to shareholders reached HKD 0.98 billion, up 14.8% year-on-year. The revenue growth was primarily driven by the export of leaf products and cigarettes, while profit growth was supported by the same export businesses and a decrease in financing costs [4] - The board proposed a final dividend of HKD 0.33 per share, in addition to an interim dividend of HKD 0.19 per share, bringing the total annual dividend to HKD 0.52 per share, which is a 13.0% increase year-on-year [4] Business Segment Performance - The revenue from the leaf product import business was HKD 95.38 billion, a 15.6% increase year-on-year, despite a 1.0% decrease in import volume to 110,800 tons. The gross profit was HKD 0.772 billion, down 6.5% year-on-year [5] - The leaf product export business saw a revenue of HKD 24.81 billion, up 20.4% year-on-year, with an export volume of 86,100 tons, a 3.1% increase. The gross profit surged by 86.8% to HKD 0.157 billion, attributed to enhanced customized services and improved pricing strategies [5] - The cigarette export business generated HKD 16.66 billion in revenue, a 5.9% increase year-on-year, with an export volume of 3.228 billion sticks, down 3.3%. The gross profit rose by 37.2% to HKD 0.381 billion, driven by the expansion of self-operated channels [5] - The new tobacco product export business faced a significant decline, with revenue dropping to HKD 0.64 billion, down 52.5% year-on-year, and an export volume decrease of 51.2% [5] - The Brazilian operations reported a revenue of HKD 8.29 billion, down 21.0% year-on-year, with a decrease in export volume to 30,300 tons, down 4.2% [5] Strategic Outlook - The company aims to leverage both organic growth and external expansion to seize new development opportunities, focusing on international market expansion and investment platform positioning. It plans to enhance supply chain collaboration and diversify its product offerings [6] - The company is committed to increasing its market presence in the cigar segment and addressing geopolitical challenges affecting the international supply chain [7] Financial Projections - The company is expected to achieve total revenues of HKD 15.18 billion, HKD 16.28 billion, and HKD 17.44 billion for the years 2026, 2027, and 2028, respectively, with year-on-year growth rates of 4%, 7%, and 7% [8] - The net profit attributable to shareholders is projected to be HKD 1.08 billion, HKD 1.21 billion, and HKD 1.37 billion for the same years, reflecting growth rates of 10%, 12%, and 13% [8] - The earnings per share (EPS) is forecasted to be HKD 1.56, HKD 1.75, and HKD 1.98 for 2026, 2027, and 2028, respectively, with corresponding price-to-earnings (P/E) ratios of 24.74, 22.03, and 19.48 [8]

Investment Rating - The investment rating for China Tobacco Hong Kong (6055.HK) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on recent developments and financial projections [1]. Core Insights - The company has signed a framework agreement with Leaf Trading, increasing the annual trading limit for tobacco sales to HKD 6.7 million, HKD 8.4 million, and HKD 9.8 million for the years 2026 to 2028 respectively [1]. - A framework agreement has also been established with China Tobacco International (North America) for the export of tobacco leaves to new regions, with the annual trading limits raised significantly for 2026 and 2027, reflecting increases of 538.4% and 456.8% respectively [1][2]. - The adjustments in trading limits are based on past orders, current orders, expected demand, and the company's business expansion, indicating strong confidence in future business growth [2]. - The company aims to diversify its customer base and attract potential buyers from broader regions, particularly in Southeast Asia [2]. Financial Summary - The company’s total revenue is projected to grow from HKD 13,074 million in 2024 to HKD 18,823 million in 2027, with year-on-year growth rates of 10%, 16%, 12%, and 11% respectively [4]. - The net profit attributable to the parent company is expected to increase from HKD 854 million in 2024 to HKD 1,310 million in 2027, with growth rates of 43%, 19%, 16%, and 11% respectively [4]. - Earnings per share (EPS) is forecasted to rise from HKD 1.23 in 2024 to HKD 1.89 in 2027 [4]. - The company is positioned as the exclusive operational entity for international business expansion and related trade for China Tobacco International, with a strong potential for mergers and acquisitions to accelerate growth [3]. Operational Performance - In the first half of 2025, the company reported tobacco leaf import/export revenues of HKD 839.9 million and HKD 115.6 million, representing year-on-year increases of 23.5% and 25.9% respectively [2]. - The company’s cigarette export revenue was HKD 115.6 million, showing a slight increase of 0.8%, while new tobacco products experienced a significant decline of 66.5% [2]. - The Brazilian operations reported a revenue of HKD 19.5 million, down 50.3% year-on-year, indicating some operational challenges [2].

Core Viewpoint - The report from Southwest Securities indicates that the performance of the light industry sector in 2025 is expected to be flat, with cyclical and traditional manufacturing valuations under pressure, while packaging, exports, and personal care sectors show differentiated performance [1] 2025 Sector Review - In 2025, the light industry sector experienced relatively flat performance, with traditional cyclical and manufacturing companies facing valuation pressure. However, the packaging and printing sectors benefited from price increases and cross-industry transformations, leading to better stock performance [1] - The export sector showed some differentiation due to tariff policy disruptions, with companies that have balanced production capacity, strong demand resilience, and low tariff impact performing better [1] - The personal care sector achieved excess returns in the first half of the year but entered a valuation digestion phase in the second half due to intensified competition in e-commerce channels. However, domestic brands are expected to continue their growth trajectory due to product structure optimization and channel expansion [1] 2026 Stock Selection Strategy - The focus will be on undervalued cyclical assets as valuation recovery is anticipated amid changes in the bulk commodity cycle, gradually realizing allocation value [2] - There is a need to balance the valuation and growth potential of new consumption and export sectors, favoring high-growth or low-valuation, high-safety stocks [2] - Four main lines of focus for stock selection include: 1. Gradually emphasizing undervalued cyclical stocks, particularly in the paper sector, which is expected to see price increases driven by "anti-involution" and traditional peak season factors, with net profit per ton likely to recover [2] 2. Export stocks with strong demand resilience and manufacturing capabilities are still considered valuable for allocation, especially those with good growth potential in niche categories and minimal tariff impact [2] 3. Domestic personal care brands are expected to see upward trends in market share and growth potential due to rapid product iteration and competitive pricing [2] 4. New consumption trends in AI glasses, new tobacco products, pet supplies, and trendy toys are expected to continue their upward trajectory, contributing to the growth of the consumption sector [2] Recommended Stocks - Recommended stocks include Sun Paper, Bohui Paper, Weigao Medical, Baiya Co., Nobon Co., Yiyi Co., Mengbaihe, and Gujia Home [3]

Summary of the Conference Call for Smoore International Company Overview - Smoore International is transitioning from an electronic vapor company to a platform company focused on heated not-burn (HNB) technology, collaborating with firms like British American Tobacco to advance new tobacco products in response to the declining traditional cigarette market [2][5]. Industry Trends - The global traditional cigarette market is experiencing a continuous decline, with a significant drop in per capita smoking rates in the U.S. by 30% to 40% since 1970. The smoking population and consumption have decreased by approximately 1% annually over the past 20 years [7]. - New tobacco products, including HNB and oral products, are seen as key to overcoming the challenges faced by traditional tobacco companies. HNB and oral products are more suitable for large traditional tobacco firms, while the vapor electronic cigarette market is dominated by Chinese manufacturers [10]. Key Points on Smoore's Business - Smoore's HNB products are gaining market share in Japan, Italy, and Poland, indicating strong market performance and growth potential. For instance, Japan saw a 1.4% increase in market share within three months [11]. - The market valuation of Smoore is considered conservative, with future growth expected primarily from HNB business expansion. Achieving sales of over 10 billion units by 2026 could lead to a significant leap in performance [13]. - Smoore's U.S. subsidiary is focused on the medical vaporization sector and has applied for FDA certification, investing approximately 400 million yuan annually in R&D. This segment is expected to become a new growth point within three years [19]. Financial Projections and Market Expectations - Smoore has set ambitious market capitalization targets of 300 billion, 400 billion, and 500 billion yuan by 2025, despite its current valuation being in the hundreds of billions [4]. - The traditional electronic vapor market is stabilizing, with an expected annual growth rate of over 10% [3][18]. - The company anticipates that its HNB business could contribute significantly to its valuation, with estimates suggesting a sales share of 10-15% from HNB products, potentially leading to substantial profit elasticity [16][17]. Future Outlook - The domestic new tobacco market in China is expected to grow significantly, with Smoore positioned to benefit from this shift. The potential transition towards new tobacco products in China could create vast market opportunities [14]. - The medical vaporization segment is seen as a third growth curve for Smoore, with expectations for commercialization and revenue generation within three years [19][20]. Conclusion - Smoore International is strategically positioned to capitalize on the evolving tobacco landscape, with a focus on HNB technology and medical applications. The company's growth potential is supported by its innovative R&D efforts and collaborations with major tobacco firms, setting the stage for a promising future in the new tobacco market.